Albuquerque, NM: MedPharmics has been selected to conduct AstraZeneca/Oxford COVID-19 vaccine study.

_The study is planned to begin in August with the goal of signing up 340 research volunteers._

MedPharmics is excited to announce its participation in a global vaccine study to fight the COVID-19 pandemic. Partnering with AstraZeneca and Oxford University on their highly anticipated vaccine, we are dedicated to helping eradicate COVID-19 and help distribute the more than 2 billion doses of investigational vaccine.

Adults 18 years of age or older, who are healthy or medically stable are welcome to participate. Volunteers have a 2 in 3 chance of receiving the study vaccine and a 1 in 3 chance of receiving placebo.

Subjects will be excluded if:
- they have had a prior COVID-19 infection
- are on medications that can affect the immune system (e.g. chronic use of corticosteroids)
- have a history of a severe reaction to any previous vaccine

The study will last two years. During this time, there will be seven routine visits and two phone calls. The vaccine is administered in two injections, one month apart. A blood draw will be performed at each routine visit. Trial participants will also be seen and evaluated if they should develop symptoms of COVID-19. Females of child-bearing potential must agree to highly effective means of birth control during the 28 days before the first injection and for 60 days after the second injection.

Volunteers who enroll will be compensated for time and travel.

Contact:
MedPharmics LLC
883 Lead Avenue SE
Suite B
Albuquerque, NM 87102
505.243.1627